Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of medicines that benefit patients with medical needs. Co. has two compounds in development, Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy intended for the treatment of patients with Exocrine Pancreatic Insufficiency, often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy. We show 5 historical shares outstanding datapoints in our ANTH shares outstanding history coverage, used to compute ANTH market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ANTH market cap history over the course of time is important for investors
interested in comparing ANTH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ANTH versus a peer is one thing; comparing
ANTH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ANTH can fluctuate over the course of history.
With this page we aim to empower investors researching ANTH by allowing them to research the ANTH market cap history. |